Bayer Schering Pharma, Prometheus Reach Agreement on Oncology Mutational Analyses | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories and Bayer Schering Pharma today said they have executed an oncology-focused mutational analyses services agreement, building on a deal reached between the two parties earlier this year.

Information gleaned from the new agreement may lead to better patient stratification in clinical studies and hasten the development of new cancer diagnostics and treatments, Prometheus said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.